- Home
- Publications
- Publication Search
- Publication Details
Title
Progress in systemic therapy for triple-negative breast cancer
Authors
Keywords
-
Journal
Frontiers of Medicine
Volume -, Issue -, Pages -
Publisher
Springer Science and Business Media LLC
Online
2020-08-13
DOI
10.1007/s11684-020-0741-5
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Type I Protein Arginine Methyltransferases Overexpression Promotes Transformation and Potentiates Her2/Neu–Driven Tumorigenesis
- (2019) Zachary L. Watson et al. CANCER RESEARCH
- Time for a “Plan B” in Peritoneal Metastatic Disease
- (2019) Claudio Tripodo CANCER RESEARCH
- Tumor mutational load predicts survival after immunotherapy across multiple cancer types
- (2019) Robert M. Samstein et al. NATURE GENETICS
- Insights into Molecular Classifications of Triple-Negative Breast Cancer: Improving Patient Selection for Treatment
- (2019) Ana C. Garrido-Castro et al. Cancer Discovery
- Sacituzumab Govitecan-hziy in Refractory Metastatic Triple-Negative Breast Cancer
- (2019) Aditya Bardia et al. NEW ENGLAND JOURNAL OF MEDICINE
- OlympiAD final overall survival and tolerability results: Olaparib versus chemotherapy treatment of physician’s choice in patients with a germline BRCA mutation and HER2-negative metastatic breast cancer
- (2019) M E Robson et al. ANNALS OF ONCOLOGY
- Targeting the PI3-kinase pathway in triple-negative breast cancer
- (2019) J Pascual et al. ANNALS OF ONCOLOGY
- Immune induction strategies in metastatic triple-negative breast cancer to enhance the sensitivity to PD-1 blockade: the TONIC trial
- (2019) Leonie Voorwerk et al. NATURE MEDICINE
- Identification of Genetic Mutations in Cancer: Challenge and Opportunity in the New Era of Targeted Therapy
- (2019) Jing Jin et al. Frontiers in Oncology
- FAIRLANE, a double-blind placebo-controlled randomized phase II trial of neoadjuvant ipatasertib plus paclitaxel for early triple-negative breast cancer
- (2019) M Oliveira et al. ANNALS OF ONCOLOGY
- Homologous recombination deficiency in triple negative breast cancer
- (2019) Carmen Belli et al. BREAST
- Cancer treatment and survivorship statistics, 2019
- (2019) Kimberly D. Miller et al. CA-A CANCER JOURNAL FOR CLINICIANS
- Open-Label Clinical Trial of Niraparib Combined With Pembrolizumab for Treatment of Advanced or Metastatic Triple-Negative Breast Cancer
- (2019) Shaveta Vinayak et al. JAMA Oncology
- Niraparib in Patients with Newly Diagnosed Advanced Ovarian Cancer
- (2019) Antonio González-Martín et al. NEW ENGLAND JOURNAL OF MEDICINE
- Veliparib with First-Line Chemotherapy and as Maintenance Therapy in Ovarian Cancer
- (2019) Robert L. Coleman et al. NEW ENGLAND JOURNAL OF MEDICINE
- Platinum-based neoadjuvant chemotherapy in triple-negative breast cancer: a systematic review and meta-analysis
- (2018) F Poggio et al. ANNALS OF ONCOLOGY
- Convergence to Cure Cancer through Research: A Message from the New Editor-in-Chief
- (2018) Chi Van Dang CANCER RESEARCH
- Carboplatin in BRCA1/2-mutated and triple-negative breast cancer BRCAness subgroups: the TNT Trial
- (2018) Andrew Tutt et al. NATURE MEDICINE
- Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries
- (2018) Freddie Bray et al. CA-A CANCER JOURNAL FOR CLINICIANS
- AZD5363 plus paclitaxel versus placebo plus paclitaxel as first-line therapy for metastatic triple-negative breast cancer (PAKT): A randomised, double-blind, placebo-controlled, phase II trial.
- (2018) Peter Schmid et al. JOURNAL OF CLINICAL ONCOLOGY
- Talazoparib in Patients with Advanced Breast Cancer and a Germline BRCA Mutation
- (2018) Jennifer K. Litton et al. NEW ENGLAND JOURNAL OF MEDICINE
- Long-term Clinical Outcomes and Biomarker Analyses of Atezolizumab Therapy for Patients With Metastatic Triple-Negative Breast Cancer
- (2018) Leisha A. Emens et al. JAMA Oncology
- Survival analysis of carboplatin added to an anthracycline/taxane-based neoadjuvant chemotherapy and HRD score as predictor of response—final results from GeparSixto
- (2018) S Loibl et al. ANNALS OF ONCOLOGY
- Pembrolizumab monotherapy for previously untreated, PD-L1-positive, metastatic triple-negative breast cancer: cohort B of the phase II KEYNOTE-086 study
- (2018) S Adams et al. ANNALS OF ONCOLOGY
- Pembrolizumab monotherapy for previously treated metastatic triple-negative breast cancer: cohort A of the phase II KEYNOTE-086 study
- (2018) S Adams et al. ANNALS OF ONCOLOGY
- Atezolizumab and Nab-Paclitaxel in Advanced Triple-Negative Breast Cancer
- (2018) Peter Schmid et al. NEW ENGLAND JOURNAL OF MEDICINE
- Molecular alterations in triple-negative breast cancer—the road to new treatment strategies
- (2017) Carsten Denkert et al. LANCET
- Ipatasertib plus paclitaxel versus placebo plus paclitaxel as first-line therapy for metastatic triple-negative breast cancer (LOTUS): a multicentre, randomised, double-blind, placebo-controlled, phase 2 trial
- (2017) Sung-Bae Kim et al. LANCET ONCOLOGY
- Olaparib for Metastatic Breast Cancer in Patients with a Germline BRCA Mutation
- (2017) Mark Robson et al. NEW ENGLAND JOURNAL OF MEDICINE
- Identification of genetic determinants of breast cancer immune phenotypes by integrative genome-scale analysis
- (2017) Wouter Hendrickx et al. OncoImmunology
- A randomized adaptive phase II/III study of buparlisib, a pan-class I PI3K inhibitor, combined with paclitaxel for the treatment of HER2− advanced breast cancer (BELLE-4)
- (2016) M. Martín et al. ANNALS OF ONCOLOGY
- Homologous Recombination Deficiency (HRD) Score Predicts Response to Platinum-Containing Neoadjuvant Chemotherapy in Patients with Triple-Negative Breast Cancer
- (2016) M. L. Telli et al. CLINICAL CANCER RESEARCH
- Efficacy of Neoadjuvant Carboplatin plus Docetaxel in Triple-Negative Breast Cancer: Combined Analysis of Two Cohorts
- (2016) Priyanka Sharma et al. CLINICAL CANCER RESEARCH
- Pembrolizumab in Patients With Advanced Triple-Negative Breast Cancer: Phase Ib KEYNOTE-012 Study
- (2016) Rita Nanda et al. JOURNAL OF CLINICAL ONCOLOGY
- Triple-negative breast cancer: challenges and opportunities of a heterogeneous disease
- (2016) Giampaolo Bianchini et al. Nature Reviews Clinical Oncology
- Pembrolizumab versus Chemotherapy for PD-L1–Positive Non–Small-Cell Lung Cancer
- (2016) Martin Reck et al. NEW ENGLAND JOURNAL OF MEDICINE
- Better pathologic complete response and relapse-free survival after carboplatin plus paclitaxel compared with epirubicin plus paclitaxel as neoadjuvant chemotherapy for locally advanced triple-negative breast cancer: a randomized phase 2 trial
- (2016) Pin Zhang et al. Oncotarget
- First-in-Human Trial of a Novel Anti-Trop-2 Antibody-SN-38 Conjugate, Sacituzumab Govitecan, for the Treatment of Diverse Metastatic Solid Tumors
- (2015) A. N. Starodub et al. CLINICAL CANCER RESEARCH
- EMERGE: A Randomized Phase II Study of the Antibody-Drug Conjugate Glembatumumab Vedotin in Advanced Glycoprotein NMB–Expressing Breast Cancer
- (2015) Denise A. Yardley et al. JOURNAL OF CLINICAL ONCOLOGY
- Impact of the Addition of Carboplatin and/or Bevacizumab to Neoadjuvant Once-per-Week Paclitaxel Followed by Dose-Dense Doxorubicin and Cyclophosphamide on Pathologic Complete Response Rates in Stage II to III Triple-Negative Breast Cancer: CALGB 40603 (Alliance)
- (2015) William M. Sikov et al. JOURNAL OF CLINICAL ONCOLOGY
- TBCRC009: A Multicenter Phase II Clinical Trial of Platinum Monotherapy With Biomarker Assessment in Metastatic Triple-Negative Breast Cancer
- (2015) Steven J. Isakoff et al. JOURNAL OF CLINICAL ONCOLOGY
- Cisplatin plus gemcitabine versus paclitaxel plus gemcitabine as first-line therapy for metastatic triple-negative breast cancer (CBCSG006): a randomised, open-label, multicentre, phase 3 trial
- (2015) Xi-Chun Hu et al. LANCET ONCOLOGY
- PD-1 Blockade in Tumors with Mismatch-Repair Deficiency
- (2015) Dung T. Le et al. NEW ENGLAND JOURNAL OF MEDICINE
- Trop-2 is a novel target for solid cancer therapy with sacituzumab govitecan (IMMU-132), an antibody-drug conjugate (ADC)*
- (2015) David M. Goldenberg et al. Oncotarget
- Predicting response and survival in chemotherapy-treated triple-negative breast cancer
- (2014) A Prat et al. BRITISH JOURNAL OF CANCER
- Neoadjuvant carboplatin in patients with triple-negative and HER2-positive early breast cancer (GeparSixto; GBG 66): a randomised phase 2 trial
- (2014) Gunter von Minckwitz et al. LANCET ONCOLOGY
- TGF-β inhibition enhances chemotherapy action against triple-negative breast cancer
- (2013) Neil E. Bhola et al. JOURNAL OF CLINICAL INVESTIGATION
- Optimal strategies for the treatment of metastatic triple-negative breast cancer with currently approved agents
- (2012) F. Andre et al. ANNALS OF ONCOLOGY
- Ploidy and Large-Scale Genomic Instability Consistently Identify Basal-like Breast Carcinomas with BRCA1/2 Inactivation
- (2012) T. Popova et al. CANCER RESEARCH
- The use of an antibody drug conjugate, glembatumumab vedotin (CDX-011), for the treatment of breast cancer
- (2012) Christopher H Keir et al. EXPERT OPINION ON BIOLOGICAL THERAPY
- Comprehensive molecular portraits of human breast tumours
- (2012) Daniel C. Koboldt et al. NATURE
- TGFβ induces the formation of tumour-initiating cells in claudinlow breast cancer
- (2012) Alejandra Bruna et al. Nature Communications
- Telomeric Allelic Imbalance Indicates Defective DNA Repair and Sensitivity to DNA-Damaging Agents
- (2012) Nicolai J. Birkbak et al. Cancer Discovery
- Identification of human triple-negative breast cancer subtypes and preclinical models for selection of targeted therapies
- (2011) Brian D. Lehmann et al. JOURNAL OF CLINICAL INVESTIGATION
- Identification and Characterization of NVP-BKM120, an Orally Available Pan-Class I PI3-Kinase Inhibitor
- (2011) S.-M. Maira et al. MOLECULAR CANCER THERAPEUTICS
- Molecular Stratification of Triple-Negative Breast Cancers
- (2011) C. M. Perou ONCOLOGIST
- Triple-Negative Breast Cancer
- (2010) William D. Foulkes et al. NEW ENGLAND JOURNAL OF MEDICINE
- Supervised Risk Predictor of Breast Cancer Based on Intrinsic Subtypes
- (2009) Joel S. Parker et al. JOURNAL OF CLINICAL ONCOLOGY
Create your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create NowBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started